Targeting EZH2, genetically or pharmacologically, increased GATA6 expression and reduced tumor aggressiveness, suggesting that EZH2 inhibitors could be a therapeutic strategy to induce a less aggressive, more therapy-susceptible PDAC subtype [101]. This evidence concerns the gene EZH2 and neoplasm.